Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

GCI Health appoints Aneeb Sharif as EMEA head of policy

Sharif most recently served as head of policy and patient engagement at Syneos Health

- PMLiVE

Communicating with HCPs through AI takes finesse, flexibility and the human touch

While AI’s influence is growing across drug discovery, clinical trials and supply chains, it doesn’t provide that peer-to-peer discussion and sharing of opinions that HCPs want and need

- PMLiVE

New Webinar: The AI-Driven Future of Medical Education for Pharma

Imagine MedEd that thinks, adapts, and delivers unprecedented insights. Better yet, experience if for yourself in our upcoming pharma-exclusive webinar, "Unlocking Brainpower: The AI-Driven Future of Medical Education for Pharma."...

Impetus Digital

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

FDA approves CSL’s Andembry to prevent hereditary angioedema attacks

The genetic disorder affects approximately one in 10,000 to one in 50,000 people worldwide

- PMLiVE

Galderma shares positive long-term data for Nemluvio in prurigo nodularis

The chronic skin disorder is estimated to affect up to 181,000 people in the US

- PMLiVE

Maximising the potential of AI in pharma

The use of AI in pharma can expedite drug development and manufacturing, enabling novel medicines to get to underserved communities more quickly

- PMLiVE

Local muscle, global impact

Why local market input is the early commercialisation superpower

- PMLiVE

Driving Impact in Diabetes Care: Medscape to Present 11 Publications at ADA’s 85th Scientific Sessions

Medscape Education is proud to present 11 publications at the American Diabetes Association 85th Scientific Sessions, taking place June 20–23 in Chicago. These presentations reflect our commitment to advancing diabetes care...

Medscape Education

- PMLiVE

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition

The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD

- PMLiVE

AstraZeneca’s Ultomiris shows promise in rare post-transplant complication

There are currently no approved treatment options for HSCT-TMA

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links